Relationship of antibodies to endotoxin core to mortality in medical patients with sepsis syndrome

Intensive Care Medicine

Volumn 25, Issue 5, 1999, Pages 435-444

  Strutz, F ^a   Heller, G ^a   Krasemann, K ^a   Krone, B ^a   Muller G A ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Endotoxin; Endotoxin core antibodies; Medical intensive care; Prognostic factors; Sepsis score; Sepsis syndrome

Indexed keywords

ANTIBODY; ENDOTOXIN; ENDOTOXIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INDWELLING CATHETER; INTENSIVE CARE; MAJOR CLINICAL STUDY; MORTALITY; PROGNOSIS; SEPSIS; SEPTIC SHOCK; TREATMENT PLANNING; VEIN PUNCTURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; BIOLOGICAL MARKERS; COHORT STUDIES; ENDOTOXINS; FEMALE; GERMANY; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOTHERAPY; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; PROGNOSIS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0032968238     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001340050877     Document Type: Article

References (40)

1. 1. Centers for Disease Control (1990) Increase in National Hospital Discharge Survey rates for septicemia. MMWR 39: 31-34
2. 2. Veterans Administration Systemic Sepsis Cooperative Study Group (1987) Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317: 659-665
3. 3. Kreger BE, Craven DE, McCabe WR (1980) Gram-negative bacteremia. IV Re-evaluation of clinical features and treatment in 612 patients. Am J Med 68: 344-355
4. 4. Corriveau CC, Danner RL (1993) Anti-endotoxin therapies for septic shock. Infect Agents Dis 2: 44-52
5. 5. Gallay P, Heumann D, Le Roy D, Barras C, Glauser M-P (1994) Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice. Proc Natl Acad Sci USA 91: 7922-7926
6. 6. Davies MG, Hagen P-O (1997) Systemic inflammatory response syndrome. Br J Surg 84: 920-935
7. 7. Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324: 429-436
8. 8. Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 266: 1097-1102
9. 9. Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines HD, Quenzer RW, Iberti TJ, Macintyre N, Schein RM (1995) A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 23: 994-1006
10. 10. Scott BB, Barclay GR (1987) Endotoxin-polymyxin complexes in an improved enzyme-linked immunosorbent assay for IgG antibodies in blood donor sera to gram-negative endotoxin core glycolipids. Vox Sang 52: 272-280
11. 11. Barclay GR, Scott BB, Wright IH, Rogers PN, Smith DGE, Poxton IR (1989) Changes in anti-endotoxin IgG antibody and endotoxaemia in three cases of gram-negative septic shock. Circ Shock 29: 93-106
12. 12. Rylatt D, Wilson K, Kemp BE, Elms MJ, Manickavsagam B, Shi W, Cox A, McArthur M-J, O'Hara J, Corbett ME, Bundesen PG, Ng KP, Ong G, Smith N, Hillyard CJ (1995) A rapid test for endotoxin in whole blood. In: Levin J, Alving CR, Munford RS, Redl H (eds) Bacterial endotoxins. Lipopolysaccharides, from genes to therapy. Wiley-Liss, New York, pp 165-174
13. 13. Bennett-Guerrero E, Ayuso L, Hamilton-Davies C, White WD, Barclay GR, Smith PK, King SA, Muhlbaier LH, Newman MF, Mythen MG (1997) Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery. JAMA 277: 646-650
14. 14. Soong CV, Halliday MI, Barclay GR, Hood JM, Rowlands BJ, Barros D'Sa AAB (1997) Intramucosal acidosis and systemic host responses in abdominal aortic aneurysms. Crit Care Med 25: 1472-1479
15. 15. Jackson SK, Parton J, Shortland G, Stark JM, Thompson EN (1990) Serum immunoglobulins to endotoxin core glycolipid: acute leukaemia and other cancers. Arch Dis Child 65: 771-773
16. 16. McCabe WR, DeMaria A, Berberich H, Johns MA (1972) Type-specific and cross-reactive antibodies in gram-negative bacteremia. N Engl J Med 287: 261-267
17. 17. Schedel I, Dreikhausen U, Nentwig B, Hockenschnieder M, Rauthmann D, Balikcioglu S, Coldewey R, Deicher H (1991) Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med 19: 1104-1113
18. 18. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA (1989) Sepsis syndrome: a valid clinical entity. Crit Care Med 17: 389-393
19. 19. Redl H, Bahrami S, Leichtfried G, Schlag G (1992) Special collection and storage tubes for blood endotoxin and cytokine measurements. Clin Chem 38: 764-765
20. 20. Barclay GR, Scott BB (1987) Serological relationships between Escherichia coli and Salmonella smooth-and rough-mutant lipopolysaccharides as revealed by enzyme-linked immunosorbent assay for human immunoglobulin G antiendotoxin antibodies. Infect Immun 55: 2706-2714
21. 21. Goldie AS, Fearon KCH, Ross JA, Barclay GR, Jackson RE, Grant IS, Ramsay G, Blyth AS, Howie JC (1995) Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA 274: 172-177
22. 22. Elebute EA, Stoner HB (1983) The grading of sepsis. Br J Surg 70: 29-31
23. 23. Grundmann R, Hornung M (1988) Verlaufskontrolle septischer Patienten auf der Intensivstation mit Hilfe von "Sepsisscore", Endotoxin-und AT-III-Bestimmung. Langenbecks Arch Chir 373: 166-172
24. 24. Lang TA, Secic M (1997) How to report statistics in medicine. Annotated guidelines for authors, editors, and reviewers. American College of Physicians, Philadelphia
25. 25. Talan DA (1993) Recent developments in our understanding of sepsis: evaluation of anti-endotoxin antibodies and biological response modifiers. Ann Emerg Med 22: 1871-1890
26. 26. Warren HS (1997) Strategies for the treatment of sepsis. N Engl J Med 336: 952-953
27. 27. Doig GS, Martin CM, Sibbald WJ (1997) Polymyxin-dextran antiendotoxin pretreatment in an ovine model of normotensive sepsis. Crit Care Med 25: 1956-1961
28. 28. Christ WJ, Asumo O, Robidoux ALC, Perez M, Wang Y, Dubue GR, Gavin WE, Hawkins LD, McGuiness PD, Mullarkey MA, Lewis MD, Kishi Y, Kawata T, Bristol JR, Rose JR, Rossignol DP, Kobayashi S, Hishinuma I, Kimura A, Asakawa N, Katayama K, Yamatsu I (1995) E5531, a pure endotoxin antagonist of high potency. Science 268: 80-83
29. 29. Knaus WA, Sun X, Nystrom P-O, Wagner DP (1992) Evaluation of definitions for sepsis. Chest 101: 1656-1662
30. 30. Dionigi R, Dominioni L, Jemos V, Cremaschi R, Bobbio-Pallavicini F, Ballabio A (1985) Sepsis score and complement factor B for monitoring severely septic surgical patients and for predicting their survival. Eur Surg Res 17: 269-280
31. 31. Expert Panel (1994) The problem of sepsis. Intensive Care Med 20: 300-304
32. 32. Brandtzaeg P, Kierulf P, Gaustad P, Skulherg A, Bruun JN, Halvorsen S, Sorensen E (1989) Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 159: 195-204
33. 33. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE (1991) Endotoxemia in septic shock. Chest 99: 169-175
34. 34. Stumacher RJ, Kovnat MJ, McCabe WR (1973) Limitations of the usefulness of the limulus assay for endotoxin. N Engl J Med 288: 1261-1264
35. 35. Barriere SL, Lowry SF (1995) An overview of mortality risk prediction in sepsis. Crit Care Med. 23: 376-393
36. 36. Curley PJ, McMahon MJ, Lancaster F, Banks RE, Barclay GR, Shefta J, Boylston AW, Wicher JT (1993) Reduction in circulating levels of CD4-positive lymphocytes in acute pancreatitis: relationship to endotoxin, interleukin 6 and disease severity. Br J Surg 80: 1312-1315
37. 37. Wakefield CH, Barclay GR, Fearon KC, Goldie AS, Ross JA, Grant IS, Ramsay G, Howie JC (1998) Proinflammatory mediator activity, endogenous antagonists and the systemic inflammatory response in intra-abdominal sepsis. Scottish Sepsis Intervention Group. Br J Surg 85: 818-825
38. 38. Barclay GR (1995) Endogenous endotoxin-core antibody (EndoCab) as a marker of endotoxin exposure and a prognostic indicator: a review. In: Levin J, Alving CR, Munford RS, Redl H (eds) Bacterial endotoxins, lipopolysaccharides from genes to therapy. Wiley-Liss, New York, pp 263-272
39. 39. Sibbald WJ, Vincent J-L (1995) Round table conference on clinical trials for the treatment of sepsis. Crit Care Med 23: 394-399
40. 40. Dominioni L, Dionigi R, Zanello M, Chiaranda M, Acquarolo A, Ballabio A, Sguotti C (1991) Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Arch Surg 126: 236-240